Evaluation of efficacy and safety of gefitinib as monotherapy in Chinese patients with advanced non-small cell lung cancer and very poor performance status

BMC Research Notes

Volumn 1, Issue , 2008, Pages

  Wei, Zhong ^a   Mengzhao, Wang ^a   Li, Zhang ^a   Longyun, Li ^a   Xiaotong, Zhang ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77951450899     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-1-102     Document Type: Article

References (11)

1. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. JH Schiller D Harrington CP Belani C Langer A Sandler J Krook J Zhu DH Johnson, N Eng J Med 2002 346 92 8 10.1056/NEJMoa011954 (Pubitemid 34438899)
2. Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors. K Nakagawa T Tamura S Negoro S Kudoh N Yamamoto N Yamamoto K Takeda H Swaisland I Nakatani M Hirose RP Dong M Fukuoka, Ann Oncol 2003 14 922 30 10.1093/annonc/mdg250 12796031
3. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. MH Cohen GA Williams R Sridhara G Chen R Pazdur, Oncologist 2003 8 303 6 10.1634/theoncologist.8-4-303 12897327
4. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. M Fukuoka S Yano G Giaccone T Tamura K Nakagawa JY Douillard Y Nishiwaki J Vansteenkiste S Kudoh D Rischin R Eek T Horai K Noda I Takata E Smit S Averbuch A Macleod A Feyereislova RP Dong J Baselga, J Clin Oncol 2003 21 2237 46 10.1200/JCO.2003.10.038 12748244
5. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. MG Kris RB Natale RS Herbst TJ Lynch Jr D Prager CP Belani JH Schiller K Kelly H Spiridonidis A Sander KS Albain D Cella MK Wolf SD Averbuch JJ Ochs AC Kay, JAMA 2003 290 2149 58 10.1001/jama.290.16.2149 14570950
6. Retrospective analysis of the predictive factors associated with the response and survival benefit of gefitinib in patients with advanced non-small cell lung cancer. H Kaneda K Tamura T Kurata H Uejima K Nakagawa M Fukuoka, Lung Cancer 2004 46 247 54 10.1016/j.lungcan.2004.04.032 15474673
7. Activating mutation in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. TJ Lynch DW Bell R Sordella S Gurubhagavatula RA Okimoto BW Brannigan PL Harris SM Haserlat JG Supko FG Haluska DN Louis DC Christiani J Settleman DA Haber, N Engl J Med 2004 350 2129 39 10.1056/NEJMoa040938 15118073
8. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. JG Paez PA Jänne JC Lee S Tracy H Greulich S Gabriel P Herman FJ Kaye N Lindeman TJ Boggon K Naoki H Sasaki Y Fujii MJ Eck WR Sellers BE Johnson M Meyerson, Science 2004 304 1497 1500 10.1126/science.1099314 15118125
9. Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in Chinese patients with non-small cell lung cancer. XL Mu LY Li XT Zhang MZ Wang RE Feng QC Cui HS Zhou BQ Guo, Clin Cancer Res 2005 11 4289 94 10.1158/1078-0432.CCR-04-2506 15958609
10. Single-agent gefitinib in patients with untreated advanced non-small-cell lung cancer and poor performance status: a Minnie Pearl Cancer Research Network Phase II Trial. DR Spigel JD Hainsworth ER Burkett HA Burris DA Yardley M Thomas SF Jones NR Dickson DC Scullin JE Bradof JR Rubinsak JE Brierre FA Greco, Clin Lung Cancer 2005 7 127 32 10.3816/CLC.2005.n.028 16179100
11. Activity of gefitinib in advanced non-small-cell lung cancer with very poor performance status. GC Chang KC Chen TY Yang MC Yin CP Lin BI Kuo JY Hsu, Invest New Drugs 2005 23 73 7 10.1023/B:DRUG.0000047108.39129.7c 15528983